NWBO (Northwest Biotherapeutics) Cash And Cash Equivalents : $2.18 Mil (As of Dec. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Northwest Biotherapeutics Cash And Cash Equivalents?

Northwest Biotherapeutics's quarterly cash and cash equivalents increased from Jun. 2024 ($2.88 Mil) to Sep. 2024 ($2.94 Mil) but then stayed the same from Sep. 2024 ($2.94 Mil) to Dec. 2024 ($2.18 Mil).

Northwest Biotherapeutics's annual cash and cash equivalents declined from Dec. 2022 ($6.97 Mil) to Dec. 2023 ($2.13 Mil) but then increased from Dec. 2023 ($2.13 Mil) to Dec. 2024 ($2.18 Mil).

Northwest Biotherapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Northwest Biotherapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics Cash And Cash Equivalents Chart

Northwest Biotherapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

9.98

15.17

6.97

2.13

2.18

Northwest Biotherapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															2.13	2.48	2.88	2.94	2.18

Northwest Biotherapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Northwest Biotherapeutics (OTCPK:NWBO) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Northwest Biotherapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Northwest Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (OTCPK:NWBO) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

NBYB:Germany

Address

4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814

Website

https://www.nwbio.com

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.

Executives

Navid Malik	director	1 CHOLMELEY PARK, HIGHGATE, LONDON X0 N6 5ET
Marnix L Bosch	officer: Chief Technical Officer	22322 20TH AVENUE SE, STE 250, BOTHELL WA 98021
Alton L Boynton	director, officer: Chief Scientific Officer	22322 20TH AVENUE SE, STE 150, BOTHELL WA 98021
Leslie J. Goldman	officer: See Remarks	C/O NORTHWEST BIOTHERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 800, NEW YORK NY 20814
Linda F Powers	director, 10 percent owner, officer: President and CEO	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Jerry J Jasinowski	director	C/O HARSCO CORP, P O BOX 8888, CAMP HILL PA 17001-8888
Jean M. Davis	officer: See Remarks	4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Susan B Bayh	director	WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Black Cofer	director	4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Woodford Investment Management Llp	10 percent owner	27 OLD GLOUCESTER STREET, LONDON X0 WC1N 3AX
Cf Woodford Equity Income Fund	10 percent owner	C/O WOODFORD INVESTMENT MANAGEMENT LTD, 9400 GARSINGTON ROAD, OXFORD X0 OX4 2HN
Cognate Bioservices, Inc.	10 percent owner	7513 CONNELLEY DRIVE, HANOVER MD 21076
Robert A Farmer	director	10205 COLLINS AVE PENTHOUSE 6, MIAMI BEACH FL 33154
Toucan General Ii, Llc	10 percent owner	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Hemphill Robert F Jr.	10 percent owner	7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814